Zenrelia

Zenrelia Ilunocitinib 8.5mg Tablet for Dogs

Zenrelia (ilunocitinib) is the NEW once-daily JAK inhibitor for allergic and atopic dermatitis in dogs. Expect rapid itch relief from day one, with nearly 50% more itchy dogs returning to normal*,¹,². Zenrelia offers continuous itch reduction, a well-tolerated safety profile¹, and convenient once-daily dosing in multiple strengths for effective, long-term management.

• Works Fast: For dogs suffering from allergic and atopic dermatitis, Zenrelia delivers rapid itch relief, with visible improvement in itch observed from day one¹. This quick action provides immediate comfort for canine patients.
• Excellent Efficacy: Zenrelia gets nearly 50% more itchy dogs back to normal than Apoquel*,¹,². In the head-to-head study, 77% of Zenrelia-treated dogs achieved clinically normal itch levels2 compared to 53% of Apoquel-treated dogs*,¹.
• Simple to Use: Zenrelia is indicated for dogs from 12 months of age and 3 kg body weight. Containing the new active ingredient ilunocitinib, this flavourless tablet is given once daily from the start. Zenrelia comes in 4 strengths and is dosed once daily at 0.6-0.8mg/kg with or without food.
• Continuous, Sustained Itch Control: Benefit from continuous, sustained itch control with Zenrelia. Its consistent, once-daily dosing ensures continuous itch reduction and no rebound of itch, providing long-term comfort and stability for dogs with chronic allergic and atopic dermatitis.
• Global Expertise: With over 500,000 dogs treated globally³, Zenrelia has an impressive track record of successful application^. This extensive real-world experience highlights Zenrelia's efficacy and safety, supporting high confidence among veterinarians and owners worldwide.